1. Home
  2. PCSA vs MGRX Comparison

PCSA vs MGRX Comparison

Compare PCSA & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.08

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.42

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
MGRX
Founded
2011
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
7.1M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
PCSA
MGRX
Price
$2.08
$0.42
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
192.2K
21.6M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.17
EPS
N/A
N/A
Revenue
$5,000.00
$456,021.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.26
52 Week High
$8.88
$2.75

Technical Indicators

Market Signals
Indicator
PCSA
MGRX
Relative Strength Index (RSI) 42.93 44.66
Support Level $2.07 $0.31
Resistance Level $2.47 $0.49
Average True Range (ATR) 0.18 0.08
MACD -0.05 -0.02
Stochastic Oscillator 8.86 19.21

Price Performance

Historical Comparison
PCSA
MGRX

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Share on Social Networks: